Company AroCell AB

Equities

AROC

SE0003883990

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Ratings for AroCell AB

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
0.426 ^SEK	+3.90%		+4.41%	-2.52%

May. 03	AroCell AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 18	Swedish Diagnostics Company AroCell Secures US Patent	MT

AroCell publ AB is a Sweden-based diagnostic Company engaged in the development of markers for determination of cell growth (TK 210) and apoptosis. The Company's principal product candidate, TK-immuno/hem, is a test for monitoring and follow up of blood cancer. The test is based on a patented technology, which have already been evaluated in an early product prototype ELISA method. Apart from that, the Company develops a marker for solid tumor cancer disease. The AroCell cooperates with partners within development, production and sales.

Number of employees: 22

SEK in Million	2022	Weight	2023	Weight	Delta
Blood and Urine Tests 98.2 %	37	98.8 %	42	98.2 %	+15.66%
License 1.8 %	0	1.2 %	1	1.8 %	+72.87%

SEK in Million	2022	Weight	2023	Weight	Delta
Sweden 100.0 %	37	100.0 %	43	100.0 %	+16.37%

Managers	Title	Age	Since
Anders Hultman CEO	Chief Executive Officer	50	18-11-30
Lars Jakobsson DFI	Director of Finance/CFO	67	-
Gustav Sten COO	Chief Operating Officer	-	18-12-31
Gunnar Steineck CTO	Chief Tech/Sci/R&D Officer	-	16-12-31
Kiran Kumar Jagarlamudi CTO	Chief Tech/Sci/R&D Officer	-	14-12-31
Alona Nyberg IRC	Investor Relations Contact	-	18-12-31
Gunnar Wahlberg SAM	Sales & Marketing	54	20-12-31
Tina Yang PRN	Corporate Officer/Principal	-	16-12-31
Filip Fogdestam PRN	Corporate Officer/Principal	-	13-12-31
Michael Brobjer PRN	Corporate Officer/Principal	64	18-12-07

Members of the board	Title	Age	Since
Clas Runnberg BRD	Director/Board Member	72	22-12-31
Gunnar Steineck CTO	Chief Tech/Sci/R&D Officer	-	16-12-31
Max Pihlqvist CHM	Chairman	37	21-12-31
Eva Nordström BRD	Director/Board Member	54	19-12-31
Agneta Tufvesson Alm BRD	Director/Board Member	-	21-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	230,361,066	102,183,486 ( 44.36 %)	0	44.36 %

Name	Equities	%	Valuation
Arvernus Capital AG 0.1912 %	440,492	0.1912 %	17 721 kr

AroCell AB

Karlsbodavägen 39

168 67, Bromma Stockholm

+46 87 99 67 50

http://www.arocell.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
AROCELL AB	-2.52%	9.32M
MODERNA, INC.	+22.10%	46.55B
LONZA GROUP AG	+46.45%	41.84B
IQVIA HOLDINGS INC.	-3.12%	40.84B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B
CELLTRION, INC.	-6.30%	28.27B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B
MEDPACE HOLDINGS, INC.	+44.52%	13.69B
BIO-TECHNE CORPORATION	+0.19%	12.18B

Other Biotechnology & Medical Research